Re: Shareholder Value

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

KOO-KOO2

Rank: Treasurer [?]

Points: 10765 [?]

Votes: 39 Score: 2.3 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Shareholder Value

in response to

Re: Shareholder Value

jbuffett62

posted on Aug 07, 2021 12:02PM

Don missed an excellent opportunity to put out an IPO for Zenith in late 2019 before the top-line results were announced for RVX, BOM. He would have capitalized on the Apabetalone hype of the sister company Resverlogix and before "ZHCLF" started to trade and take hold on the OTC Market.